Patents by Inventor Lea Eisenbach
Lea Eisenbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230242611Abstract: MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR ? chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR ? chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.Type: ApplicationFiled: February 9, 2023Publication date: August 3, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Rachel Lea EISENBACH, David BASSAN, Yosi GOZLAN, Esther TZEHOVAL, Nir FRIEDMAN, Erez GREENSTEIN
-
Publication number: 20220211758Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.Type: ApplicationFiled: January 13, 2022Publication date: July 7, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Rachel Lea EISENBACH, Yosi GOZLAN, Esther TZEHOVAL
-
Patent number: 11273178Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.Type: GrantFiled: August 6, 2018Date of Patent: March 15, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Rachel Lea Eisenbach, Yosi Gozlan, Esther Tzehoval
-
Publication number: 20210030856Abstract: The present invention pertains to a novel cell based tumor vaccine platform. The invention provides a method for modifying antigen presenting cells (APCs) to present both MHC class I and/or MHC class II peptides in context of improved peptide presentation protein complexes in order to increase activation of a patient's immune response. In this invention, an MHC II mRNA dendritic cell based vaccine platform was developed to activate CD4+T cells in patients and to enhance the anti-tumor response. The invariant chain (Ii) was modified and the semi-peptide CLIP was replaced with an MHCII binding peptide sequences of tumor associated antigens. These chimeric MHC II constructs are presented by APCs and induce proliferation of tumor specific CD4+T cells. The invention provides the constructs, proteins, nucleic acids, recombinant cells, as well as medical applications of these products.Type: ApplicationFiled: March 26, 2019Publication date: February 4, 2021Applicants: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts, Yeda Research and Development Co., Ltd.Inventors: Rachel Lea Eisenbach, Esther Tzehoval, Gal Cafri, Adi Sharbi Yunger, Mareike Grees
-
Publication number: 20190031733Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.Type: ApplicationFiled: August 6, 2018Publication date: January 31, 2019Applicant: Yeda Research and Development Co. Ltd.Inventors: Rachel Lea EISENBACH, Yosi GOZLAN, Esther TZEHOVAL
-
Patent number: 10081663Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.Type: GrantFiled: August 2, 2013Date of Patent: September 25, 2018Assignee: Yeda Research and Development Co., Ltd.Inventors: Lea Eisenbach, Yosi Gozlan, Esther Tzehoval
-
Patent number: 8741315Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.Type: GrantFiled: September 11, 2008Date of Patent: June 3, 2014Assignees: Yeda Research and Development Co. Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Ilan Volovitz, Lea Eisenbach, Irun R. Cohen, Zvi Ram, Shimon Slavin
-
Publication number: 20140065111Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.Type: ApplicationFiled: August 2, 2013Publication date: March 6, 2014Inventors: Lea Eisenbach, Yosi Gozlan, Esther Tzehoval
-
Patent number: 8420078Abstract: A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and/or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject.Type: GrantFiled: February 21, 2006Date of Patent: April 16, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Arthur Machlenkin, Adrian Paz, Boaz Tirosh, Esther Tzehoval
-
Patent number: 7960507Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: July 27, 2010Date of Patent: June 14, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas, Arthur Machlenkin, Esther Tzehoval
-
Patent number: 7906620Abstract: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.Type: GrantFiled: July 28, 2003Date of Patent: March 15, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Lior Carmon, Arthur Machlenkin, Adrian Paz, Esther Tzehoval, Matityahu Fridkin
-
Publication number: 20100291127Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: July 27, 2010Publication date: November 18, 2010Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: LEA EISENBACH, BOAZ TIROSH, EREZ BAR-HAIM, ADRIAN PAZ, MATITYAHU FRIDKIN, CHERYL FITZER-ATTAS, ARTHUR MACHLENKIN, ESTHER TZEHOVAL
-
Patent number: 7795224Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: December 2, 2008Date of Patent: September 14, 2010Assignee: Yeda Research and Development Co., Ltd.Inventors: Lea Eisenbach, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Publication number: 20100189750Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.Type: ApplicationFiled: September 11, 2008Publication date: July 29, 2010Applicants: Yeda Research And Development Co. Ltd., The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical CenterInventors: Ilan Volovitz, Lea Eisenbach, Irun R. Cohen, Zvi Ram, Shimon Slavin
-
Publication number: 20100129410Abstract: A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and/or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject.Type: ApplicationFiled: February 21, 2006Publication date: May 27, 2010Inventors: Lea Eisenbach, Arthur Machlenkin, Adrian Paz, Boaz Tirosh, Esther Tzehoval
-
Publication number: 20090136462Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: December 2, 2008Publication date: May 28, 2009Applicant: YEDA RESEARCH AND DEVELOPMENT CO. Ltd.Inventors: Lea EISENBACH, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Patent number: 7531629Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: March 29, 2006Date of Patent: May 12, 2009Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Adrian Paz, Matityahu Fridkin
-
Publication number: 20060263342Abstract: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.Type: ApplicationFiled: July 28, 2003Publication date: November 23, 2006Applicant: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Lior Carmon, Arthur Machlenkin, Adrian Paz, Esther Tzehoval, Matityahu Fridkin
-
Publication number: 20060194730Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: March 29, 2006Publication date: August 31, 2006Applicant: YEDA RESEARCH AND DEVELOPMENT CO. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Patent number: 7084249Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: July 29, 1999Date of Patent: August 1, 2006Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas